Trimethoprim use in early pregnancy and the risk of miscarriage: A register-based nationwide cohort study

Epidemiology and Infection

Volumn 141, Issue 8, 2013, Pages 1749-1755

  Andersen, J T ^a,b   Petersen, M ^a,b   Jimenez Solem, E ^a,b   Broedbaek, K ^a,b   Andersen, E W ^c   Andersen, N L ^d   Afzal, S ^a,b   Torp Pedersen, C ^e,f   Keiding, N ^c   Poulsen, H E ^a,b,f  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Mental Health Centre Copenhagen   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibiotics; birth defects; epidemiology; pregnancy

Indexed keywords

TRIMETHOPRIM;

ADULT; AGE DISTRIBUTION; ARTICLE; BIRTH; COHORT ANALYSIS; CONCEPTION; CONTROLLED STUDY; DENMARK; DRUG EXPOSURE; EDUCATIONAL STATUS; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; INDUCED ABORTION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; REGISTER; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ADULT; ANTI-INFECTIVE AGENTS, URINARY; COHORT STUDIES; DENMARK; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; SOCIOECONOMIC FACTORS; TRIMETHOPRIM; YOUNG ADULT;

EID: 84880348137     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812002178     Document Type: Article

References (29)

1. Schweitzer BI, Dicker AP, Bertino Jr. Dihydrofolatereductase as a therapeutic target. FASEB Journal 1990; 4: 2441-2452.
2. Baird DT. Mode of action of medical methods of abortion. Journal of the American Medical Womens Association 2000; 55: 121-126.
3. Hernandez-Diaz S, et al. Folic acid antagonists during pregnancy and the risk of birth defects. New England Journal of Medicine 2000; 343: 1608-1614.
4. Hernandez-Diaz S, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. American Journal of Epidemiology 2001; 153: 961-968.
5. Czeizel AE, Toth M, Rockenbauer M. Population-based case control study of folic acid supplementation during pregnancy. Teratology 1996; 53: 345-351.
6. Berry RJ, et al. Prevention of neural-tube defects with folic acid in China. New England Journal of Medicine 1999; 341: 1485-1490.
7. Wald N. Prevention of neural-tube defects - results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-7.
8. Werler MM, et al. Multivitamin supplementation and risk of birth defects. American Journal of Epidemiology 1999; 150: 675-682.
9. Yang QH, et al. Does periconceptional multivitamin use reduce the risk for limb deficiency in offspring? Epidemiology 1997; 8: 157-161.
10. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. American Journal of Medical Genetics 1996; 62: 179-183.
11. Botto LD, et al. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: Results from a population-based, case-control study. Pediatrics 1996; 98: 911-917.
12. Smulders YM, et al. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352: 1827-1828.
13. Goldberg AB, Greenberg MB, Darney PD. Drug therapy: Misoprostol and pregnancy. New England Journal of Medicine 2001; 344: 38-47.
14. Grimes DA, Creinin MD. Induced abortion: An overview for internists. Annals of Internal Medicine 2004; 140: 620-626.
15. UNAIDS. Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS; 2000.
16. Andersen TF, et al. The Danish National Hospital Register - a valuable source of data for modern health sciences. Danish Medical Bulletin 1999; 46: 263-268.
17. Knudsen LB. The Danish Fertility Database. Danish Medical Bulletin 1998; 45: 221-225.
18. The Danish National Board of Health. Project regarding data quality in the National Hospital Register [in Danish]. Copenhagen: The Danish National Board of Health; 2004.
19. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Danish Medical Bulletin 1997; 44: 445-448.
20. von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
21. Sorensen HT, et al. Identification of patients treated with strong analgesics: An assessment of two Danish information systems with respect to epidemiological research. Journal of Medical Systems 1996; 20: 57-65.
22. Kumar S. Occupational, environmental and lifestyle factors associated with spontaneous abortion. Reproductive Sciences 2011; 18: 915-930.
23. Di Prima FA, et al. Antiphospholipid syndrome during pregnancy: The state of the art. Journal of Prenatal Medicine 2011; 5: 41-53.
24. Buss L, et al. Spontaneous abortion: A prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants. Acta Obstetrica et Gynecologia Scandinavica 2006; 85: 467-475.
25. Stover J, Fahnestock M. Coverage of selected services for HIV/AIDS prevention, Care, and treatment in lowand middle-income countries in 2005. Washington, DC: Constella Futures, POLICY Project, 2006.
26. UNAIDS. Report on the global HIV/AIDS epidemic 2008. Geneva: UNAIDS; 2008.
27. Wiktor SZ, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: A randomised controlled trial. Lancet 1999; 353: 1469-1475.
28. Nunn AJ, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: Randomised clinical trial. British Medical Journal 2008; 337: A257.
29. Mermin J, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-1434.